Does Neurogene (NGNE) Have the Potential to Rally 203.28% as Wall Street Analysts Expect?
HC Wainwright & Co. Maintains Buy on Neurogene, Lowers Price Target to $60
Neurogene: Q3 Earnings Snapshot
Neurogene Reports Third Quarter 2026 Financial Results and Highlights Recent Updates
Neurogene Q3 EPS $(1.05) Beats $(1.36) Estimate
Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Neurogene to Participate in Upcoming Investor Conferences
HC Wainwright & Co. Reiterates Buy on Neurogene, Maintains $65 Price Target
Neurogene Presents New Data at ESGCT Congress that Reinforce Key Differentiators of NGN-401 Gene Therapy for Rett Syndrome
Neurogene To Present Data Related To NGN-401 Gene Therapy Program For Rett Syndrome At ESGCT 33rd Annual Congress; New Preclinical Data Expected To Further Validate NGN-401’s Differentiated Design
Neurogene Announces Upcoming Presentations Highlighting Key Differentiators of NGN-401 for Rett Syndrome at the ESGCT 33rd Annual Congress
JP Morgan Initiates Coverage On Neurogene with Overweight Rating, Announces Price Target of $60
Neurogene 13G Filing Shows Jennison Associates Reports 11.1% Stake In Co. As Of Sept. 30
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Neurogene to Participate in H.C. Wainwright 28th Annual Global Investment Conference
Canaccord Genuity Maintains Buy on Neurogene, Lowers Price Target to $166
Guggenheim Maintains Buy on Neurogene, Raises Price Target to $81
HC Wainwright & Co. Maintains Buy on Neurogene, Lowers Price Target to $65
Neurogene Reports Second Quarter 2026 Financial Results and Highlights Recent Updates
Neurogene Q2 EPS $(1.53) Misses $(1.39) Estimate
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.